Events & Presentations
Board of Directors
Historic Stock Lookup
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics
June 21, 2017 | Press Release
Galectin Therapeutics Announces Important Milestones towards Completion of NASH CX Trial
June 13, 2017 | Press Release
Autoimmune Disease Patent Granted to Galectin Therapeutics
June 6, 2017 | Press Release
Why did you choose to become the CEO of Galectin Therapeutics?
Are you conducting clinical trials with GR-MD-02? What results have you seen so far?
Can you give me a quick overview of Galectin Therapeutics and the opportunity it sees for GR-MD-02?
Why are the results of the GR-MD-02 psoriasis study so promising?
Why is the NASH-CX trial so important?
See all videos
Galectin Therapeutics, Inc.
Financial Tear Sheet
Filings & Reports
Stock price updates every 30 minutes.
Latest Corporate Presentation
Media Fact Sheet
Corporate Fact Sheet
© 2017 Galectin Therapeutics Inc. - All Rights Reserved
Disclaimer: This site may contain